[Anty-VEGF therapy in the treatment of myopic macular choroidal neovascularization--cases report].
OBJECTIVE
Myopia is the second most frequent cause of CNV after AMD. Since the introduction verteporfin photodynamic therapy and anti-angiogenic drugs into clinical practice, major changes occurred in the treatment of subfoveal exudative maculopathy associated with myopia.The aim of the paper is to present the effect of intravitreal injections ranibizumab (Lucentis) for myopic choroidal neovascularization.


METHODS
The study included two patients (25 and 55 years old women) with high myopia. Diagnosis and monitoring of the treatment were based on fluorescein angiography and optical coherence tomography.


RESULTS
In 55-years old woman after two injections central retinal leakage decreased in fluorescein angiography and optical coherence tomography and visual acuity improved of two lines (10 letters). After 9 months follow-up in 25 years old woman's after three injections of Lucentis, visual acuity improved of three lines on ETDRS chart (15 letters). The leakage in fluorescein angiography was closed.


CONCLUSIONS
Intravitreal injections therapy of ranibizumab may be a therapeutic option for CNV associated with myopia. It causes chance for decreased central retinal thickness and increased visual acuity, particularly in view of the young patients. One must take note of the other illness associated with CNV in myopic eyes like as epiretinal membranes or vitreoretinal tractions.
Figurska
Małgorzata
M
Kliniki Okulistyki Wojskowego Instytutu Medycznego w Warszawie.
Stankiewicz
Andrzej
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods; D006801:Humans; D007267:Injections; D008875:Middle Aged; D009216:Myopia / Q000150:complications* / Q000473:pathology; D000069579:Ranibizumab; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects*; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab